Heroin, cocaine, and alcohol addictions, alone and in combination, along with their multiple and frequent medical complications (including hepatitis B and C, AIDS, and psychiatric comorbidity) remain the major medical problems confronting our nation and much of the world. Effective treatments must be based on a fundamental understanding of the biological bases of each specific addictive disease, including the effects of chronic exposure to specific drugs of abuse and the interaction with environment and genetic factors. Our NIH-NIDA P60 Treatment Research Center, """"""""Treatment of Addictions: Biological Correlates,"""""""" will continue to identify and study the dynamic molecular, neurobiological, and behavioral changes caused by heroin and cocaine. Research will focus on the endogenous opioid system, to elucidate its importance in the biological basis of addictive diseases, and interactions with related neurotransmitters and neuropeptides, emphasis on dopaminergic and glutamatergic systems, and stress-responsive systems. All laboratory and clinical research studies, and the Research Cores, have been developed on an interactive basis with thematic integration for the entire Center. Bidirectional translational research is a hallmark of the work of this Center. Findings from basic and applied clinical research are used to formulate specific hypotheses and develop novel animal models. Findings from laboratory research (such as vasopressin alterations) are applied into innovative clinical research. The specific research projects include: 1) studies of the effect of exposure, withdrawal, and re-exposure to heroin or cocaine, dynamic neurobiological adaptations in the opioid system underlying addictive-like behavioral changes;2) effects of drugs of abuse on stress-responsive brain systems and hypothalamic-pituitary-adrenal axis function;3) cocaine-induced synaptic plasticity in limbic brain regions;and 4) alterations in neuroendocrine stress responsivity in specific addictive diseases without or with codependency or comorbidity. Increasing effectiveness of existing treatments and developing novel treatments depends on expanding our insights into the molecular neurobiology of addictions, which is the primary goal of these projects, each utilizing five core resources, including a Research Training Core. Thematic integration and scientific interaction fosters synergism, which only a multidisciplinary center can provide.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Comprehensive Center (P60)
Project #
5P60DA005130-24
Application #
7848972
Study Section
Special Emphasis Panel (ZDA1-RXL-E (29))
Program Officer
Gordon, Harold
Project Start
1992-09-27
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
24
Fiscal Year
2010
Total Cost
$3,056,419
Indirect Cost
Name
Rockefeller University
Department
Biology
Type
Other Domestic Higher Education
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Butelman, Eduardo Roque; Bacciardi, Silvia; Maremmani, Angelo Giovanni Icro et al. (2017) Can a rapid measure of self-exposure to drugs of abuse provide dimensional information on depression comorbidity? Am J Addict 26:632-639
Valenza, Marta; Picetti, Roberto; Yuferov, Vadim et al. (2016) Strain and cocaine-induced differential opioid gene expression may predispose Lewis but not Fischer rats to escalate cocaine self-administration. Neuropharmacology 105:639-650
Garzón, Miguel; Pickel, Virginia M (2016) Electron microscopic localization of M2-muscarinic receptors in cholinergic and noncholinergic neurons of the laterodorsal tegmental and pedunculopontine nuclei of the rat mesopontine tegmentum. J Comp Neurol 524:3084-103
Zhou, Yan; Leri, Francesco; Cummins, Erin et al. (2015) Individual differences in gene expression of vasopressin, D2 receptor, POMC and orexin: vulnerability to relapse to heroin-seeking in rats. Physiol Behav 139:127-35
Zhou, Y; Kreek, M J (2015) Persistent increases in rat hypothalamic POMC gene expression following chronic withdrawal from chronic ""binge"" pattern escalating-dose, but not steady-dose, cocaine. Neuroscience 289:63-70
Zhou, Yan; Kreek, Mary Jeanne (2014) Alcohol: a stimulant activating brain stress responsive systems with persistent neuroadaptation. Neuropharmacology 87:51-8
Mayer-Blackwell, B; Schlussman, S D; Butelman, E R et al. (2014) Self administration of oxycodone by adolescent and adult mice affects striatal neurotransmitter receptor gene expression. Neuroscience 258:280-91
Garzón, Miguel; Pickel, Virginia M (2013) Somatodendritic targeting of M5 muscarinic receptor in the rat ventral tegmental area: implications for mesolimbic dopamine transmission. J Comp Neurol 521:2927-46
Proudnikov, Dmitri; Randesi, Matthew; Levran, Orna et al. (2013) Polymorphisms of the kappa opioid receptor and prodynorphin genes: HIV risk and HIV natural history. J Acquir Immune Defic Syndr 63:17-26
Levran, Orna; Peles, Einat; Randesi, Matthew et al. (2013) Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics 14:755-68

Showing the most recent 10 out of 167 publications